The company is currently developing a drug called amifampridine phosphate, with the proposed tradename of Firdapse, for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder that causes muscle weakness and fatigue. Catalyst has completed a successful clinical trial for LEMS and is conducting additional trials for other related disorders. They are committed to prioritizing the perspective of the patient community and maintaining passion, trust, and integrity in their work.